Globeimmune Net Total Equity Issued/Repurchased 2013-2016 | GBIM
Globeimmune net total equity issued/repurchased from 2013 to 2016. Net total equity issued/repurchased can be defined as the sum of all preferred and common equity transactions regarding a company's own stock.
Globeimmune Annual Net Total Equity Issued/Repurchased
(Millions of US $) |
| 2015 |
$N/A |
| 2014 |
$17 |
| 2013 |
$0 |
| 2012 |
$0 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Medical - Generic Drugs |
$0.000B |
$0.000B |
|
GlobeImmune, Inc. is a biopharmaceutical company. It is focused on developing products for the treatment of cancer and infectious diseases based on its proprietary Tarmogen (R) platform. The Company's products under development includes GI-5005, a product for the treatment of chronic hepatitis C infection; and GI-4000 for pancreas, non-small cell lung, colorectal, and other cancers. GlobeImmune, Inc. is based in Louisville, Colorado.
|
